【摘要】 目的观察吉西他滨单药治疗老年晚期肺癌的近期疗效、临床受益及毒副反应。方法收集Ⅲb-Ⅳ期老年非小细胞肺癌患者32例,应用吉西他滨单药化疗(1000mg/m2,第1,8天静脉滴注),21-28d为1周期,2周期后评价疗效及毒副反应。结果本组32例患者中,完全缓解(CR)0例,部分缓解(PR)9例,稳定(SD)13例,进展(PD)10例,有效率28.1%,临床受益率(CR+PR+SD)为68.75%。患者毒副反应主要表现为骨髓抑制,以白细胞和血小板减少为主,白细胞减少Ⅰ-Ⅱ度46.9%,Ⅲ-Ⅳ12.5%,血小板减少Ⅰ-Ⅱ度发生率为53.1%,Ⅲ度9.4%,无Ⅳ度减少。消化道反应轻微,未见明显心肝肾毒性。结论吉西他滨单药治疗疗效好,低毒安全,可改善老年晚期肺癌患者的生活质量,延长生存期。更多还原

【Abstract】 Objective To evaluate the efficacy,clinical benefit response and toxicity of gemcitabine in the treatment of the elderly patients with advanced non-small cell lung cancer.Methods Thirty-two elderly patients with stage Ⅲb-Ⅳ non-small cell lung cancer were treated with gemcitabine 1 000 mg/m2 at day 1 and day 8 in each 21-28-day cycle.The efficacy and toxicity were evaluated after 2 cycles.Results The total efficacy rate was 28.1%,and the clinical benefit rate was 68.75%.The main toxicities were leucopenia and thrombocytopenia.Conclusion Gemcitabine is effective in the treatment of the elderly advanced non-small cell lung cancer patients,with low toxicity and good safety.It can improve the life quality of the elderly patients and prolong their survival time.更多还原